Immuneering Corporation (NASDAQ: IMRX) appointed Andrew Gengos as chief financial officer, effective July 16, 2026, according to a company statement. Gengos previously served as CFO and head of corporate development at Terns Pharmaceuticals, which Merck & Co. acquired for $6.7 billion.

At Immuneering, Gengos will oversee financial strategy, capital allocation, investor relations, business development, and corporate development activities. The company is advancing atebimetinib, its lead oncology candidate currently in Phase 3 trials, along with a pipeline of other deep cyclic inhibitors.

"Andrew is a proven biotechnology executive with a strong track record of helping innovative companies navigate critical stages of growth and value creation," said Ben Zeskind, co-founder and CEO of Immuneering.

Gengos brings more than 25 years of biotechnology leadership experience. Prior to Terns, he served as CFO and chief business officer at Athira Pharma, Inc., now known as LeonaBio, Inc. He also held the position of chief business officer at Cyteir Therapeutics, Inc., where he led the finance organization through the company's initial public offering.

Earlier in his career, Gengos served as CEO of ImmunoCellular Therapeutics, Ltd. and Neuraltus Pharmaceuticals, Inc. He spent eight years at Amgen Inc. as vice president of strategy and corporate development, helping shape the company's strategic priorities and business development initiatives. He began his career at Morgan Stanley and later worked at McKinsey & Company.

Gengos holds an MBA from UCLA Anderson School of Management and a bachelor's degree in chemical engineering from MIT. Immuneering is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy for first-line pancreatic cancer patients.